Nurix Therapeutics (NRIX) Earnings Date & Reports
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases... Show more
NRIX is expected to report earnings to fall 8.76% to -72 cents per share on July 09
Nurix Therapeutics (NRIX) Fiscal First Quarter 2026 Earnings Recap: Revenue Miss Offset by Pipeline Momentum
Key Takeaways
- Nurix Therapeutics reported fiscal first quarter 2026 revenue of $6.3 million, down 66% from $18.5 million year-over-year, missing consensus estimates of $14.25 million.
- Net loss widened to $87.2 million, or ($0.79) per share, compared to $56.4 million, or ($0.67) per share, in the prior year quarter; EPS missed expectations of ($0.76).
- R&D expenses rose to $84.1 million from $69.7 million, driven by investments in bexobrutideg trials and manufacturing.
- Cash position remained strong at $540.7 million as of February 28, 2026, supporting ongoing clinical programs.
- Pipeline advances include ongoing Phase 2 enrollment for bexobrutideg in r/r CLL and plans for Phase 3 initiation by mid-2026.
- Stock dipped 4.6% on April 8 but recovered, closing up 4.6% from the post-earnings low by April 14.
Earnings Context and Why It Matters
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation (TPD) therapies for cancer and inflammatory diseases, released fiscal first quarter 2026 results on April 8, 2026. This quarter ended February 28, 2026, aligning with the company's fiscal year ending November 30. As a pre-revenue biotech heavily reliant on collaboration revenue from partners like Gilead, Sanofi, and Pfizer, earnings spotlight pipeline execution amid rising R&D spend. Investors watch these reports closely for progress on lead candidate bexobrutideg, a BTK degrader in pivotal trials for relapsed/refractory chronic lymphocytic leukemia (r/r CLL), and cash burn sustainability. With TPD emerging as a promising modality, Nurix's updates influence sector sentiment and valuation in a competitive biotech landscape.
For the fiscal first quarter 2026, ended February 28, 2026, Nurix reported collaboration revenue of $6.3 million, primarily from Pfizer and Gilead agreements, down sharply from $18.5 million in the year-ago quarter due to the conclusion of certain Sanofi research terms. This fell well short of Wall Street's $14.25 million consensus.
Research and development (R&D) expenses climbed 21% to $84.1 million, fueled by higher personnel costs, clinical trial acceleration for bexobrutideg's Phase 2 DAYBreak CLL-201 study, and manufacturing scale-up for Phase 3. General and administrative (G&A) expenses increased to $14.6 million from $11.7 million, tied to staffing growth. These drove a net loss of $87.2 million, or ($0.79) diluted EPS, versus consensus ($0.76) and prior-year ($0.67).
Despite misses, Nurix ended the quarter with $540.7 million in cash, cash equivalents, and marketable securities, down from $592.9 million at fiscal year-end but providing ample runway. No updated numerical guidance was offered, but management reaffirmed key milestones like Phase 3 bexobrutideg initiation by mid-2026.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your research process.
Market Reaction and Investor Sentiment
NRIX shares fell 4.6% to $15.60 on April 8, 2026, amid elevated volume of over 2 million shares, reflecting disappointment over the revenue shortfall and wider loss. However, the sell-off proved short-lived, with the stock rebounding 4.1% to $16.24 the next day and reaching $16.30 by April 14—a net recovery above pre-earnings levels. Sentiment appears buoyed by robust cash reserves and pipeline catalysts, including bexobrutideg data readouts, outweighing financial misses typical for development-stage biotechs.
Forward Outlook and Key Factors to Monitor
Investors should track Nurix's execution on bexobrutideg, its lead BTK degrader. The ongoing Phase 2 DAYBreak CLL-201 trial in r/r CLL patients post prior therapies aims to support accelerated approval, with enrollment progressing. A confirmatory Phase 3 DAYBreak CLL-306 versus pirtobrutinib is slated to start by mid-2026, a pivotal catalyst.
Broader pipeline includes zelebrudomide (BTK/IKZF degrader) in Phase 1b expansions for lymphomas, NX-1607 (CBL-B inhibitor) dose optimizations, and partnered assets like Gilead's IRAK4 degrader GS-6791 in Phase 1 and Sanofi's STAT6 degrader NX-3911 nearing IND. A new tablet formulation for bexobrutideg in autoimmune indications targets a 2026 IND filing.
Cash at $540.7 million funds operations into 2027, but rising R&D—up 21% this quarter—warrants monitoring amid collaboration revenue volatility. Upcoming milestones: updated Phase 1b data at 2026 medical meetings, Pfizer/Sanofi progress, and Q2 fiscal 2026 results in July. Industry dynamics like TPD competition and regulatory feedback on r/r CLL will shape trajectory. No full-year guidance was provided, emphasizing clinical over financial metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Advertisement
General Information
a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders
Industry Biotechnology